Skip to main content
Article

The FDA’s latest move to expand eligibility for oncology trials — a double-edged sword?

Nature Reviews Clinical Oncology
DOI: 10.1038/s41571-021-00559-0
3Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.
Get full text

Cite

CITATION STYLE

APA

Lythgoe, M. P., & Prasad, V. (2021, December 1). The FDA’s latest move to expand eligibility for oncology trials — a double-edged sword? Nature Reviews Clinical Oncology. Nature Research. https://doi.org/10.1038/s41571-021-00559-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free